Entero Therapeutics (NASDAQ:ENTO) Shares Down 3.4% – Time to Sell?

Shares of Entero Therapeutics, Inc. (NASDAQ:ENTO) dropped 3.4% during mid-day trading on Thursday . The company traded as low as $3.33 and last traded at $3.42. 23,477 shares changed hands during mid-day trading, a decline of 99% from the average session volume of 2,798,922 shares. The stock had previously closed at $3.54.

Entero Therapeutics Stock Down 9.3%

The firm has a market capitalization of $4.83 million, a PE ratio of -1.80 and a beta of 1.19. The company’s fifty day simple moving average is $4.72 and its 200 day simple moving average is $3.50.

Hedge Funds Weigh In On Entero Therapeutics

A hedge fund recently bought a new position in Entero Therapeutics stock. Virtu Financial LLC purchased a new stake in Entero Therapeutics, Inc. (NASDAQ:ENTO) during the third quarter, according to its most recent 13F filing with the SEC. The firm purchased 11,829 shares of the company’s stock, valued at approximately $59,000. Virtu Financial LLC owned approximately 0.74% of Entero Therapeutics as of its most recent filing with the SEC. 12.30% of the stock is owned by institutional investors and hedge funds.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc (NASDAQ: ENTO) is a clinical‐stage specialty pharmaceutical company dedicated to developing innovative therapies for patients suffering from rare and debilitating gastrointestinal (GI) disorders. The company leverages targeted delivery technologies designed to localize therapeutic molecules directly to affected regions of the GI tract, aiming to enhance efficacy while minimizing systemic exposure. Entero’s research and development efforts focus on addressing chronic conditions with significant unmet medical needs, including malabsorption syndromes and motility‐related GI diseases.

Entero’s pipeline features multiple lead candidates in varying stages of clinical development.